Dopaminergic agonists: Possible neurorescue drugs endowed with independent and synergistic multisites of action

Neurochemical Research

Volumn 32, Issue 10, 2007, Pages 1726-1729

  Uberti, Daniela ^a   Bianchi, Irene ^a   Olivari, Luca ^a   Ferrari Toninelli, Giulia ^a   Bonini, Sara A ^a   Memo, Maurizio ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Alzheimer's disease; Beta amyloid; Free radicals; Neurodegeneration; Oxidative stress; Parkinson's disease

Indexed keywords

DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; PERGOLIDE MESILATE; PRAMIPEXOLE;

ANTIOXIDANT ACTIVITY; ARTICLE; CLINICAL EFFECTIVENESS; DEMENTIA; DRUG ACTIVITY; DRUG MECHANISM; HUMAN; MONOTHERAPY; NEUROPROTECTION; PARKINSON DISEASE; PRIORITY JOURNAL; STIMULATION;

ANIMALS; BENZOTHIAZOLES; DEMENTIA; DOPAMINE AGONISTS; HUMANS; NEUROPROTECTIVE AGENTS; PERGOLIDE;

EID: 34548728712     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11064-007-9350-9     Document Type: Article

References (37)

1. Ogawa N, Tanaka K, Asanuma M, Kawai M, Masumizu T, Kohno M, Mori A (1994) Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro. Brain Res 657:207-213
2. Gassen M, Gross A, Youdim MB (1998) Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6-hydroxydopamine. Mov Disord 13:661-667
3. Asanuma M, Ogawa N, Nishibayashi S, Kawai M, Kondo Y, Iwata E (1995) Protective effects of pergolide on dopamine levels in the 6-hydroxydopamine- lesioned mouse brain. Arch Int Pharmacodyn Ther 329:221-230
4. Kitamura Y, Kohno Y, Nakazawa M, Nomura Y (1997) Inhibitory effects of talipexole and pramipexole on MPTP-induced dopamine reduction in the striatum of C57BL/6N mice. Jpn J Pharmacol 74:51-57
5. Cassarino DS, Fall CP, Smith TS, Bennett JP Jr (1998) Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion. J Neurochem 71:295-301
6. Zou L, Xu J, Jankovic J, He Y, Appel SH, Le W (2000) Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice. Neurosci Lett 281:167-170
7. Vu TQ, Ling ZD, Ma SY, Robie HC, Tong CW, Chen EY, Lipton JW, Carvey PM (2000) Pramipexole attenuates the dopaminergic cell loss induced by intraventricular 6-hydroxydopamine. J Neural Transm 107:159-176
8. Joyce JN, Millan MJ (2007) Dopamine D3 receptor agonists for protection and repair in Parkinson's disease. Cur Op Pharmacol 7:100-105
9. Caray PM, McGuire SO, Ling ZD (2001) Neuroprotective effects of D3 dopamine receptor agonists. Parkinsonism Relat Disord 7:213-223
10. Van Kapen JM, Eckman CB (2006) Dopamine D3 receptor agonist delivery to a model of Parkinson's disease restores the nigrostriatal pathway and improves locomotor behaviour. Neurobiol Dis 26:7272-7280
11. Parkinson Study Group (2002) Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson's disease progression. JAMA 287:1653-1661
12. Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, Lang AE, Rascol O, Ribeiro MJ, Remy P, Poewe WH, Hauser RA, Brooks DJ, REAL-PET Study Group (2003) Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 54:93-101
13. Uberti D, Piccioni L, Colzi A, Bravi D, Canonico PL, Memo M (2002) Pergolide protects SH-SY5Y cells against neurodegeneration induced by H(2)O(2). Eur J Pharmacol 434:17-20
14. Grilli M, Memo M (1999a) Possible role of NF-kappaB and p53 in the glutamate-induced pro-apoptotic neuronal pathway. Cell Death Differ 6:22-27
15. Grilli M, Memo M (1999b) Nuclear factor-kappaB/Rel proteins: a point of convergence of signalling pathways relevant in neuronal function and dysfunction. Biochem Pharmacol 57:1-7
16. Uberti D, Carsana T, Francisconi S, Ferrari Toninelli G, Canonico PL, Memo M (2004) A novel mechanism for pergolide-induced neuroprotection: inhibition of NF-kappaB nuclear translocation. Biochem Pharmacol 67:1743-1750
17. Fujita Y, Izawa Y, Ali N, Kanematsu Y, Tsuchiya K, Hamano S, Tamaki T, Yoshizumi M (2006) Pramipexole protects against H2O2-induced PC12 cell death. Naunyn Schmiedebergs Arch Pharmacol 372:257-266
18. Le WD, Jankovic J, Xie W, Appel SH (2000) Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection. J Neural Transm 107:1165-1173
19. Abramova NA, Cassarino DS, Khan SM, Painter TW, Bennett JP Jr (2002) Inhibition by R(+) or S(-) pramipexole of caspase activation and cell death induced by methylpyridinium ion or beta amyloid peptide in SH-SY5Y neuroblastoma. J Neurosci Res 67:494-500
20. Huang F, Vemuri MC, Schneider JS (2004) Modulation of ATP levels alters the mode of hydrogen peroxide-induced cell death in primary cortical cultures: effects of putative neuroprotective agents. Brain Res 997:79-88
21. Pattee GL, Post GR, Gerber RE, Bennett JP Jr (2003) Reduction of oxidative stress in amyotrophic lateral sclerosis following pramipexole treatment. Amyotroph Lateral Scler Other Motor Neuron Disord 4:90-95
22. Spina MB, Cohen G (1989) Dopamine turnover and glutathione oxidation: implications for Parkinson disease. Proc Natl Acad Sci USA 86:1398-1400
23. Dexter DT, Holley AE, Flitter WD, Slater TF, Wells FR, Daniel SE, Lees AJ, Jenner P, Marsden CD (1994) Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov Disord 9:92-97
24. Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER, Mizuno Y (1996) Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci USA 93:2696-2701
25. McKeith IG, Mosimann UP (2004) Dementia with Lewy bodies and Parkinson's disease. Parkinsonism and Relat Disord 10:S15-S18
26. Burn DJ, McKeith IG (2003) Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease. Mov Disord 18:72-79
27. Lin M.T., Beal F (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443:787-795
28. Butterfield DA (2003) Amyloid beta-peptide [1-42]-associated free radical-induced oxidative stress and neurodegeneration in Alzheimer's disease brain: mechanisms and consequences. Curr Med Chem 10:2651-2658
29. Moreira PI, Smith MA, Zhu X, Honda K, Lee HG, Aliev G, Perry G (2005) Oxidative damage and Alzheimer's disease: are antioxidant therapies useful? Drug News Perspect 18:13-19
30. Behl C. (2005) Oxidative stress in Alzheimer's disease: implications for prevention and therapy. Subcell Biochem 38:65-78
31. Aksenov MY, Aksenova MV, Carney JM, Butterfield DA (1997) Oxidative modification of glutamine synthetase by amyloid beta peptide. Free Rad Res 27:267-281
32. Barnham KJ, Masters CL, Bush AI (2004) Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov 3:205-214
33. Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, Sinha S, Schlossmacher M, Whaley J, Swindlehurst C et al (1992) Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 359:325-327
34. Boyd-Kimball D, Sultana R, Mohmmad-Abdul H, Butterfield DA (2005) Neurotoxicity and oxidative stress in D1M-substituted Alzheimer's A beta(1-42): relevance to N-terminal methionine chemistry in small model peptides. Peptides 26:665-673
35. Butterfield DA (1997) beta-Amyloid-associated free radical oxidative stress and neurotoxicity: implications for Alzheimer's disease. Chem Res Toxicol 10:495-506
36. Subramaniam R, Koppal T, Green M, Yatin S, Jordan B, Drake J, Butterfield DA (1998) The free radical antioxidant vitamin E protects cortical synaptosomal membranes from amyloid beta-peptide(25-35) toxicity but not from hydroxynonenal toxicity: relevance to the free radical hypothesis of Alzheimer's disease. Neurochem Res 23:1403-1410
37. Uberti D, Bianchi I, Olivari L, Ferrari-Toninelli G, Canonico P, Memo M (2007) Neuroprotective effect of pramipexole against beta amyloid toxicity depends on peptide aggregated states. Eur J Pharmacol, in press